Hussein Maged H, Peedikayil Musthafa Chalikandy, Zamir Zamir Ahmed, Alfadda Abdulrahman
Department of Medicine, Section of Nephrology, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia.
Department of Medicine, Section of Gastroenterology, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia.
Ann Thorac Med. 2018 Apr-Jun;13(2):117-121. doi: 10.4103/atm.ATM_194_17.
Hepatic hydrothorax (HH) is a transudative pleural effusion that complicates advanced liver cirrhosis. Cases refractory to medical treatment in the form of salt restriction and diuretics are labeled refractory hepatic hydrothorax (RHH) and may require transjugular intrahepatic portosystemic shunts (TIPSS) or even liver transplantation. Renal impairment is common in advanced liver disease, worsens its prognosis, and makes the management of HH more challenging. Successful antiviral therapy reduces some of the complications of cirrhosis secondary to hepatitis C virus (HCV) infection. We herein report two cirrhotic patients with chronic kidney disease who developed RHH which resolved after the successful treatment of their HCV infection with direct-acting antivirals (DAAs). In cases of RHH associated with HCV cirrhosis, a trial of DAAs is warranted before resorting to TIPSs or liver transplantation.
肝性胸水(HH)是一种漏出性胸腔积液,是晚期肝硬化的并发症。对于采用限盐和利尿剂治疗无效的病例,被称为难治性肝性胸水(RHH),可能需要行经颈静脉肝内门体分流术(TIPSS)甚至肝移植。肾功能损害在晚期肝病中很常见,会使预后恶化,并使HH的管理更具挑战性。成功的抗病毒治疗可减少丙型肝炎病毒(HCV)感染继发肝硬化的一些并发症。我们在此报告两名患有慢性肾脏病的肝硬化患者,他们在接受直接抗病毒药物(DAA)成功治疗HCV感染后,难治性肝性胸水得到缓解。对于与HCV肝硬化相关的RHH病例,在采取TIPS或肝移植之前,有必要试用DAA。